Deloitte report: 3 trends to watch in the life sciences sector

Despite what appears to be a steady rise in research and development expenditure, biopharma companies have recently faced mounting challenges as escalating costs, interest rate concerns, and a risk-averse regulatory setting have the potential to affect innovation and productivity.Nationally, the life sciences sector experienced a decline in overall deal activity last year — the total deal value fell to $104 billion across 122 transactions, representing a 40% decrease in value and a 30% dec